AstraZeneca

9M and Q3 2023 Results

Conference call and webcast for investors and analysts



9th November 2023

Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other thingsthe risk of failure or delay in delivery of pipeline or launch of new medicines: the risk of failure to meet regulatory or ethical requirements for medicine development or approval, the risk of failures or delays in the quality or execution of the Group’s commercial strategies, the risk of pricing, affordability, access and competitive pressures, the risk of failure to maintain supply of compliant, quality medicines, the risk of illegal trade in the Group’s medicines, the impact of reliance on third-party goods and services, the risk of failure in information technology or cybersecurity, the risk of failure of critical processes, the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives, the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce, the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change, the risk of the safety and efficacy of marketed medicines being questioned, the risk of adverse outcome of litigation and/or governmental investigations, intellectual property-related risks to our products, the risk of failure to achieve strategic plans or meet targets or expectations, the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition, the risk of failure in financial control or the occurrence of fraud, the risk of unexpected deterioration in the Group’s financial position. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

9M and Q3 2023 Results

Conference call agenda



CEO Opening Remarks	**Pascal Soriot** Chief Executive Officer	
Financial Results	**Aradhana Sarin** Chief Financial Officer	
Oncology	**Dave Fredrickson** EVP, Oncology Business	**Susan Galbraith** EVP, Oncology R&D
BioPharmaceuticals	**Ruud Dobber** EVP, BioPharmaceuticals Business	**Sharon Barr** EVP, BioPharmaceuticals R&D
Rare Disease	**Marc Dunoyer** Chief Executive Officer, Alexion	
CEO Closing Remarks, Q&A	**Pascal Soriot** Chief Executive Officer	

CEO Opening Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER



Benefitting from broad-based, diverse sources of revenue

Strong commercial performance and financial delivery in 9M 2023

Total Revenue | +5%



Core EPS | +17%

Broad-based, diverse source of Total Revenue

9M 2023 | % Total Revenue by therapy area



9M 2023 | % Total Revenue by geography



2023 guidance updated: Core EPS now expected to increase by a low double-digit to low-teens %

All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
1. COVID-19 mAbs = *Evusheld* and AZD3152, the antibody currently in development. CER = constant exchange rates; mAb = monoclonal antibody; EPS = earnings per share; CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies; ERoW = Established Rest of World.

Strong growth across regions, therapy areas

Double-digit growth across US, EM and EU

9M Total Revenue ex-COVID-19 (USD millions) and Growth vs PY



Strong growth across Oncology, CVRM, R&I and Rare Disease underpinning FY outlook

9M Total Revenue (USD millions) and Growth vs PY



All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Total Revenue and growth rates by region reflect figures ex-COVID-19 medicines. EM = Emerging Markets; EU = Europe; CER = constant exchange rates; CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies.

AstraZeneca – building the pipeline of the future

Delivering sustainable, industry-leading growth

- CELL THERAPY
- GENE THERAPY
- EPIGENETICS
- T-CELL ENGAGERS
- NOVEL ADCs
- IO BISPECIFICS
- OLIGONUCLEOTIDES
- RNA THERAPIES

Therapy area leadership, broad pipeline and focused investment to deliver transformative new medicines

ADC = antibody drug conjugate; IO = immuno-oncology; RNA = ribonucleic acid.

Financial Results



Aradhana Sarin

CHIEF FINANCIAL OFFICER

9M 2023 – Reported profit and loss



	9M 2023 $m	CER change %	% Total Revenue	Q3 2023 $m	CER change %	% Total Revenue
Total Revenue	**33,787**	**5**	**100**	**11,492**	**6**	**100**
- Product Sales	*32,466*	*4*	*96*	11,018	*5*	*96*
- Alliance Revenue	*1,004*	*99*	*3*	377	*75*	*3*
- Collaboration Revenue	*317*	*(28)*	*1*	97	*(47)*	*1*
Product Sales Gross margin	81.6%	+12 pp		81.0%	+10 pp	
Total operating expense[1]	(22,101)	6	65	(7,513)	9	65
- R&D expense	(7,862)	12	23	(2,584)	4	22
- SG&A expense	(13,845)	2	41	(4,800)	12	42
Other operating income and expense	1,233	>3x	4	70	(33)	1
Operating profit	6,959	>2x	21	1,954	69	17
Tax rate	17%			17%		
Reported EPS	**$3.22**	**>2x**		**$0.89**	**(6)**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Absolute values at actual exchange rates; changes at CER. Product Sales Gross margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
1. Total operating expense includes distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates.

9M 2023 – Core profit and loss



	9M 2023 $m	CER change %	% Total Revenue	Q3 2023 $m	CER change %	% Total Revenue
Total Revenue	**33,787**	**5**	**100**	**11,492**	**6**	**100**
- Product Sales	*32,466*	*4*	*96*	11,018	*5*	*96*
- Alliance Revenue	*1,004*	*99*	*3*	377	*75*	*3*
- Collaboration Revenue	*317*	*(28)*	*1*	97	*(47)*	*1*
Product Sales Gross margin	82.4%	+2 pp		81.4%	+1 pp	
Total operating expense[1]	(17,452)	7	52	(5,969)	6	52
- R&D expense	(7,353)	7	22	(2,485)	5	22
- SG&A expense	(9,705)	8	29	(3,355)	7	29
Other operating income and expense	1,172	>3x	3	70	(34)	1
Operating profit	11,782	16	35	3,545	9	31
Tax rate	19%			19%		
Core EPS	**$5.80**	**17**		**$1.73**	**9**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Absolute values at actual exchange rates; changes at CER. Product Sales Gross margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
1. Total operating expense includes distribution, R&D and SG&A expenses. R&D = Research & Development; SG&A = Sales, General & Administrative; EPS = earnings per share; pp = percentage points; CER = constant exchange rates.

Cash Flow, Net Debt and 2023 Financial Guidance

Continued EBITDA improvement

Net Debt bridge

$12.7bn —— **Adjusted EBITDA[2]** ——→ **$14.0bn**

Net Debt/EBITDA: 1.7x

Updated 2023 Guidance (CER)

Total Revenue

- Mid single-digit % increase
  (previously low-to-mid single-digit % increase)

Total Revenue excluding COVID-19 medicines

- Low-teens % increase
  (previously low double-digit % increase)

Core EPS

- Low double-digit to low-teens % increase
  (previously high single-digit to low double-digit % increase)

Low single digit adverse FX impact on Total Revenue
Mid single-digit adverse FX impact on Core EPS[3]

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
1.Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma share purchase liability and acquisitions of subsidiaries, net of cash acquired. 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $387m (FY 2022: $3,484m) . AstraZeneca credit ratings: Moody’s: short-term rating P-1, long-term rating A2, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. Assuming average September 2023 foreign exchange rates for October to December 2023. EBITDA = earnings before interest, tax, depreciation and amortisation; CFO = net cash inflow from operating activities; CER = constant exchange rates; EPS = earnings per share.

Capital allocation

Capital allocation strategy unchanged

Reinvestment in the business

Free cashflow post-Capex

- **Maintain a strong investment-grade credit rating**
- **Value-enhancing business development**
- **Progressive dividend policy**

Priority remains reinvesting in our business

Investments to drive future growth

- Currently >120 projects in Phase II/III development
- Investments behind launches in new indications and strengthening leadership in existing therapy areas
- Continued investments in new technologies and platforms including cell and gene therapies
- Value accretive deals
- Continue to leverage partnerships to drive innovation and bring medicines to markets quicker

>20 new approvals in major markets YTD

CAPEX = capital expenditure; YTD = year-to-date.

AstraZeneca – AI in Commercial

DRIVING FASTER, BETTER DECISION MAKING | *harnessing technology to deliver better patient outcomes*

Delivering real-time insights



Advanced analytics enhance real-time decision making

Addressing unmet needs and personalising engagement

Optimising identification of at-risk patients

>6m analysed handwritten EMR notes in 24hrs

Applying AI and deep multimodal data to identify high responders



Predicting treatment eligible patient presentation in clinic



Velcheti, V., Klump, E., Long, A., Pulmonary nodule characteristics and workup rates, 2023. AI = artificial intelligence; EMR = electronic medical record.

Oncology



Dave Fredrickson
ONCOLOGY BUSINESS

Susan Galbraith
ONCOLOGY R&D

Oncology – 9M and Q3 2023

Total Revenue +20% in 9M 2023 fueled by strong global demand growth

Oncology
9M 2023 $13.5bn, +20%



Q3 2023: key dynamics

- ***Tagrisso*** +6%, continued ADAURA and FLAURA global demand growth, short-term impact from anti-corruption campaign in CN
- ***Lynparza* PS** +8%, EU, ERoW, EM demand growth slightly offset by 2L OC label restriction, decreased PARPi use in the US
- ***Imfinzi/Imjudo*** +54%, continued strong global launch momentum
- ***Calquence*** +15%, preferred BTKi across 1L and r/r CLL
- ***Enhertu*** +86%, penetration in DB03, DB04 and new global launches uptake ex-US

- New indications: EU, JP (*Enhertu* DL02), CN (*Calquence* CLL/SLL)
- Regulatory update: US (*Tagrisso* FLAURA2 Priority Review, *Imfinzi* AEGEAN submission acceptance)

All growth rates at CER.
CER = constant exchange rates; NRDL = National Reimbursement Drug List; PS = Product Sales; EU = Europe; ERoW = Established Rest of World; EM = Emerging Markets; CN = China; 2L = 2nd-line; OC = ovarian cancer; PARPi = poly (ADP-ribose) polymerase inhibitor; BTKi = bruton tyrosine kinase inhibitor; 1L = 1st-line; r/r CLL = relapsed/refractory chronic lymphocytic leukaemia; DB03 = DESTINY-Breast03; DB04 = DESTINY-Breast04; DL02 = DESTINY-Lung02; SLL = small lymphocytic lymphoma.
Collaboration partners: Daiichi Sankyo (*Enhertu*), Merck & Co., Inc. (*Lynparza*).

Oncology – *Tagrisso* and *Calquence*

Leading value propositions, commercial execution reinforce future growth opportunity

Establishing *Tagrisso* for every *EGFR*m patient

Best-in-class QD oral regimen, leading benefit/risk profile

Stage I-III resectable

ADAURA
Adjuvant *Tagrisso*

- Expand reimbursement
- Increase referral rates (>80%) and adjuvant treated (>65%)

Stage III unresectable

LAURA
Tagrisso post-CRT

- Drive *EGFR*m testing in Stg. III unresectable

HLR H1 2024

1L metastatic

FLAURA
Tagrisso

- Support longer DoT globally (>22 mo)

FLAURA2
Tagrisso + CTx

- Address patients with highest unmet need (L858R, CNS mets)
- Further extend DoT

Calquence maintaining BTKi leadership in face of competition



LCM and combination opportunities reinforce *Tagrisso* as backbone TKI

NeoADAURA | PACIFIC-4 | SAFFRON / SAVANNAH | Dato-DXd combos

Sustained 1L CLL leadership, recovery in r/r share

Source: Based on internal new to brand prescription (NBRx) analysis by AstraZeneca UK Limited using IQVIA US National Prescription Audit Market Dynamics (NPA MD) for the period of September 2023, reflecting estimates of real-world activity.

*EGFR*m = epidermal growth factor receptor mutated; QD = once daily; 1L = 1st=line; CRT = chemoradiotherapy; SoC = standard-of-care; IO = immunotherapy; Stg. = stage; OS = overall survival; DoT = duration of therapy; mo. = months; CTx = chemotherapy; CNS = central nervous system; TKI = tyrosine kinase inhibitor; Dato-DXd = datopatomab deruxtecan; BTKi = bruton tyrosine kinase inhibitor; NBRx = new-to-brand prescription; CLL = chronic lymphocytic leukemia; r/r = relapsed refractory.

Oncology – R&D highlights

Data at WCLC and ESMO reinforce AstraZeneca leadership across tumour types



Consolidating leading position in *EGFR*m lung | FLAURA2[1,2]

- FLAURA2 – longest mPFS >29 mo
- >50% patients with CNS metastases at baseline showed complete response

FLAURA-2 patient with CNS LMD showed deep, durable response



Expanding into new tumour types in gynae | DUO-E[3]

- First IO + PARP inhibitor option for 1L advanced endometrial
- Deeper benefit with *Lynparza* in pMMR and PD-L1+ subgroups



Dato-DXd beat conventional monotherapy CTx | TL01, TB01[4,5]

- Best-in-class profile supports combination with IO
- Broad potential in earlier lines and other tumour types

	TL01	TB01
PFS Dato-DXd vs CTx	HR, 0.63	HR, 0.63
	Non-squamous 2L+ NSCLC	HR+/HER2- 2L+ mBC

*Lesions in the right precentral gyrus ("motor cortex"), patient scans with permission from FLAURA2 investigator. 1. Janne PA et al. Abstract PL03.13 presented at World Conference on Lung Cancer 2023; 2. Janne PA et al. Abstract #LBA68 presented at European Society of Medical Oncology 2023; 3. Westin S et al. Abstract #LBA41 presented at European Society of Medical Oncology 2023; 4. Ahn M et al. Abstract #LBA12 presented at European Society of Medical Oncology 2023; 5. Bardia et al. Abstract #LBA11 presented at European Society of Medical Oncology 2023. WCLC = World Conference on Lung Cancer; ESMO = European Society of Medical Oncology; *EGFR*m = epidermal growth factor receptor mutation; NSCLC = non-small cell lung cancer; 1L = 1st-line; CNS = central nervous system; CR = complete response; NEJM = New England Journal of Medicine; CTx = chemotherapy; LMD = leptomeningeal disease; MRI = magnetic resonance imaging; gynae = gynaecological; IO = immunotherapy; PARP = poly (ADP-ribose) polymerase; p/dMRR = proficient / deficient mismatch repair; PD-L1 = programmed death-ligand 1; *Imf* = *Imfinzi; Lyn* = *Lynparza*; NR = not reached; Dato-DXd = datopotamab deruxtecan; combo = combination; mPFS = median progression-free survival; HR = hazard ratio; 2L = 2nd-line; HR+ = hormone-receptor positive; HER2- = human epidermal growth factor receptor 2 negative; mBC = metastatic breast cancer. Collaboration partner: Daiichi Sankyo (Dato-DXd).

Oncology – R&D highlights

Volrustomig leading new wave of immuno-oncology bispecific molecules



Encouraging early phase data for volrustomig

first-in-class monovalent bispecific molecule targeting PD-1 and CTLA-4

1L adv. NSCLC with CTx[1]



Population (N=50)	≥30% reduction in target lesions (%)	ORR (%)
ITT (n=49)	49	40.8
PD-L1<1% (n=36)	55.6	44.4

Treatment-naïve adv. RCC patients[2]



Four bispecific Phase III trials announced

eVOLVE-Lung02 | 1L mNSCLC PD-L1 < 50%



- **eVOLVE-Cervical** | volrurstomig following ccRT in high risk LA cervical cancer
- **eVOLVE-Meso** | volrustomig + CTx then volrustomig in newly diagnosed unresect. malignant pleural mesothelioma
- **ARTEMIDE-Bil01** | rilvegostomig + CTx in biliary tract cancer after resection with curative intent

Rapidly advancing IO bispecific programmes into Phase III with potential to combine with ADCs

1. Ahn MJ et al. Abstract #LBA56 presented at European Society of Medical Oncology 2022; 2. Voss M et al. Abstract #1883MO presented at European Society of Medical Oncology 2023.
PD-(L)1 = programmed cell death (ligand) 1; CTLA-4 = cytotoxic T lymphocyte antigen 4; 1L = 1st-line; adv.= advanced; (m)NSCLC = (metastatic) non-small cell lung cancer; CTx = chemotherapy; NE = not evaluable; ORR = objective response rate; ITT = intention-to-treat; RCC = clear cell renal carcinoma; DCR = disease control rate; path/icPR = pathologic/immune confirmed complete response; PR = partial response; SD = stable disease; PD = progressive disease; R = randomise; pembro = pembrolizumab; LA = locally advanced; cCRT = concurrent chemoradiotherapy; volrust = volrustomig; observ = observation; nivo = nivolumab; ipi = ipilimumab; IO = immuno-oncology; ADC = antibody drug conjugate.
Collaboration partner: Compugen (rilvegostomig).

Oncology – R&D highlights

Establishing AstraZeneca portfolio of differentiated ADCs



Five wholly owned ADCs already in the clinic

Clinical stage trials ongoing in lung, breast, haematology, GYN/GU and GI

ADC	PRECLINICAL	PHASE I	PHASE II	PHASE III	INDICATIONS OF INTEREST
AZD8205 (B7H4) DAR 8	■	■	■		Breast, BTC, ovarian, endometrial
AZD9592 (EGFR/cMET) DAR 6	■	■			NSCLC, HNSCC
AZD5335 (FRα) DAR 8	■	■			Ovarian, lung
AZD0901 (CLDN18.2) DAR 4	■	■	■		Gastric, GEJ, pancreatic
LM-305 (GPRC5D) DAR 4	■	■			Multiple myeloma

AZD0901

Promising efficacy in gastric / GEJ cancer

BoR in gastric / GEJ cancer (IHC 2+, ≥20% TC)[1]
Phase I dose escalation / expansion



Broader clinical development programme in progress

1. Xu RH et al. Abstract 434420 presented at ASCO Virtual Plenary on 7 November 2023. ADC images for illustrative purposes only; actual drug positions may vary.
ADC = antibody drug conjugate; GYN = gynaecological; GU = genitourinary; GI = gastrointestinal; B7H4 = B7 homolog 4; DAR = drug to antibody ratio; EGFR= epidermal growth factor receptor: cMET =mesenchymal-epithelial transition factor ; FRα = folate receptor alpha; CLDN18.2 = claudin 18.2; CPRC5D = G-protein coupled receptor C family 5D; TOP1i = topoisomerase 1 inhibitor; MMAE = monomethyl auristatin E; BTC = biliary tract cancer; NSCLC = non-small cell lung cancer; HSNCC = head and neck squamous cell carcinoma; GEJ = gastroesophageal junction; BoR = best overall response; IHC = immunohistochemistry; TC = tumour cell; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; NE = not evaluable.
Collaboration partner: Keymed Biosciences (AZD0901).

Oncology – R&D highlights

In-house development and strategic collaborations expand our reach in cell therapy



Innovative armoured CAR-T programme for solid tumour

TGFβRIIDN armouring enhances potential effectiveness CAR-T in solid tumours

AZD7003 (C-CAR031)[1] | armoured GPC3

CAR copies in peripheral blood



- **Encouraging FIH data** in HCC
- **Strong expansion and persistence** of CAR-T cellular kinetics
- **Promising anti-tumour activity,** objective responses in several patients

AZD0754 | armoured STEAP2

AZD6422 | armoured Claudin 18.2

Advancing T-cell receptor therapies acquired from Neogene



cellectis
EDITING LIFE

Collaboration announced Nov 2023

Differentiated allogeneic platform

1. Designed by AstraZeneca and manufactured and developed in China by Cellular Biomedicine group.

CAR(-T) = chimeric antigen receptor(-T cell); TGFβRIIDN = dominant negative transforming growth factor β receptor II; GPC3 = Glypican 3; FIH = first-in-human; HCC = hepatocellular carcinoma; STEAP2 = human 6-transmembrane epithelial antigen of prostate 2; IND = investigational new drug.

Acquisition of Neogene Therapeutics was completed on 16 January 2023, Neogene Therapeutics is a global clinical-stage biotechnology company focused on discovery, development and manufacturing of next-generation T-cell receptor therapies.

BioPharmaceuticals

Ruud Dobber
BIOPHARMACEUTICALS BUSINESS

Sharon Barr
BIOPHARMACEUTICALS R&D



BioPharmaceuticals – 9M and Q3 2023

CVRM Total Revenue +19% in 9M 2023 and strong launch brand momentum in R&I

CVRM
9M 2023 $7.9bn, +19%



Q3 dynamics
- ***Farxiga*** +41%, demand growth outpacing SGLT2i
- ***Lokelma,*** **roxadustat** both up >30%

R&I
9M 2023 $4.7bn, +9%



Q3 dynamics
- ***Fasenra,*** +10%, continued uptake of biologics
- ***Breztri,*** +69%, to $171m, global share gains
- ***Tezspire,*** +19% QoQ, strong launches continue

V&I
9M 2023 $944m



Q3 dynamics
- **COVID-19 medicines** $nil in Q3
- ***FluMist*** +23%, new orders and phasing
- ***Beyfortus,*** first commercial sales and milestone

All growth rates at CER.
1. COVID-19 mAbs = *Evusheld* and AZD3152, the antibody currently in development
CER = constant exchange rates; CVRM = Cardiovascular, Renal and Metabolism; SGLT2i = sodium-glucose cotransporter 2 inhibitors; R&I = Respiratory and Immunology; QoQ = quarter on quarter; V&I = Vaccine and Immune Therapies; mAbs = monoclonal antibodies.
Collaboration partners: Amgen (*Tezspire*); Sanofi (*Beyfortus*).

BioPharmaceuticals – 9M and Q3 2023

Portfolio evolution enables long-term sustainable growth

Key R&I medicines grew 42% in Q3 2023

% of R&I Total Revenue



Growth of newer brands more than offset generic impact on older medicines

Tezspire market leadership within first year of launch

New-to-brand share[1] in severe uncontrolled asthma



***Tezspire* market share expansion globally within growing class**

Farxiga - substantial growth opportunity remains

Potential to increase proportion of diagnosed and treated CKD and HF patients



***Farxiga* growth strengthens foundation for next-gen CVRM**

1. Based on internal new to brand prescription (NBRx) analysis by AstraZeneca UK Limited using data from the following sources: IQVIA Japan Rx, and IQVIA Germany LRx, IQVIA PharmaScope® National and IQVIA DKM® data for the period Aug 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. 2. Sources for CKD & HF prevalence: 1Jager KJ, et al; Nephrol Dial Transplant. 2019;34(11):1803-1805. 2Vos T et al. The Lancet. 2017; 390(10100):1211–59. Analysis prepared based on: Germany, France, Italy, Spain, UK and US using AZ internal projections provided by local marketing companies. CKD prevalence and diagnosis based on Stages 2b-4a; treated to guideline is based on total SGLT2i penetration July 2023 IQVIA EMR patient record data US, EU3 and UK; Telomera patient record data for Spain. R&I = respiratory and immunology; LoE = loss of exclusivity; CKD = chronic kidney disease; CVRM = Cardiovascular, Renal and Metabolism; LCM = lifecycle management.
Collaboration partners: Amgen (*Tezspire*).

BioPharmaceuticals – R&D highlights

Advancing potential novel medicines to address unmet needs across CKD and HF



4 **potential new medicines**

tailored approach to address biological mechanisms driving disease progression

Phase III initiated zibo/dapa in CKD with high proteinuria

Phase III initiation planned before YE, baxdrostat in HTN

Broad disease epidemiology figures are based on US prevalent patients as per CDC. 1. Simone Romano et al. Internal and Emergency Medicine, 02 August 2023. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. 2. Jens van de Wouw et al. Front. Physiol., 04 September 2019 Sec. Clinical and Translational Physiology Volume 10 – 2019. 3. CKD in the General Population, NIDDK. 4. CKD Prevalence by hypertension status and year, NHANES, ~25-30% of adults diagnosed with hypertension have CKD.

dapagliflozin = *Farxiga*; m = millions; CKD = chronic kidney disease; HF = heart failure; HTN = hypertension

BioPharmaceuticals – R&D highlights

Data at ASN and ERS publication support Phase III trials

zibotentan / dapagliflozin

Chronic Kidney Disease with high proteinuria

Phase II ZENITH: UACR reduction

UACR >30mg/g signals presence of urine albumin, marker for CKD



zibo/dapa demonstrated clinically meaningful reduction in UACR across both doses

tozorakimab | IL-33 mAb

COPD	OBERON, TITANIA, MIRANDA	>2024
Severe viral LRTD	TILIA	>2024
Asthma, COPD	FRONTIER-3, FRONTIER-4 (Phase II)	UPCOMING

Phase III trial initiated, opportunity to increase patient benefit with synergistic combination treatment

Dual pathway inhibition could provide a unique opportunity in inflammatory diseases

1. Based on KDIGO guidelines; high proteinuria defined as UACR >300m/g. 2. Global Burden of Disease Study 2019, Lower Respiratory Infection collaborators 3. ACCORD-2 is a University of Southampton trial that investigated potential treatments for patients hospitalised with COVID-19 during the pandemic 4. Odds ratio adjusted for age and baseline COVID-19 severity. 5. IL-33/sST2 complex biomarker defined as patients with ≥30.15U/mL.
ASN = American Society of Nephrology; ERS = European Respiratory Society; CKD = chronic kidney disease; UACR = urine albumin-to-creatinine ratio; zibo = zibotentan; dapa = dapagliflozin (*Farxiga*); SoC = standard-of-care; IL-33 = interleukin-33; sST2 = soluble suppression of tumorigenesis-2; LRTD = lower respiratory tract disease.

BioPharmaceuticals

Accelerating presence in obesity with ECC5004, a novel once-daily oral GLP-1RA

ECCOGENE 诚益生物

ECC5004 (GLP-1RA)
global development
and commercialisation rights[1]

Potential for no titration

High bioavailability, favourable tolerability profile

Novel once-daily oral small molecule

Efficacy at low doses – 10 to 30mg

Phase II planned 2024

Significant market opportunity in obesity



1bn people living with obesity



Diabetes, dyslipidemia, hypertension, HF, renal disease, NASH

Obesity is driver for **>200 chronic diseases**

Opportunity beyond obesity to address cardiometabolic disease

Farxiga	**AZD6234** LA Amylin	**baxdrostat** ASI	**mitiperstat** MPO	**AZD5462** oRXFP1	**AZD0780** oPCSK9
on-market	Phase I	Phase III	Phase II	Phase I	Phase I

Strong track record in cardio renal metabolic diseases, opportunity for monotherapy and combinations to address broad range of co-morbid diseases

1. In China, Eccogene and AstraZeneca will operate under co-development and co-commercialisation agreement. GLP-1RA = glucagon-like peptide 1 receptor agonist; HF = heart failure; NASH = non-alcoholic steatohepatitis; LA = long-acting; ASI = aldosterone synthase inhibitor; MPO = myeloperoxidase; oRXFP1 = oral relaxin family peptide receptor 1; oPCSK9 – oral proprotein convertase subtilisin/kexin type-9.

Rare Disease

Marc Dunoyer
CHIEF EXECUTIVE OFFICER,
ALEXION



Rare Disease – 9M and Q3 2023

Strong double-digit growth in 9M 2023 with Total Revenue +12%, momentum into year-end

Total Revenue by medicine

9M 2023 $5.8bn, +12%



Q3 dynamics

- ***Ultomiris*** +49%, neurology demand, new market access; ***Soliris*** (12%), successful conversion
- ***Strensiq*** +21%, and ***Koselugo*** +81%, new patient demand

Total Revenue by region



Q3 dynamics

- **US** +9% and **EU** +8%, neurology demand
- **ERoW** +22%, neurology demand, expanded access
- **Emerging Markets** +70%, demand growth, expanded access

C5 franchise indications



Key dynamics

- Neurology growing proportion of C5 franchise
- Smaller proportion from ultra rare disease, PNH and aHUS

All growth rates at CER.
1. Includes *Kanuma* and *Koselugo*. 2. Q3 2021 Total Revenue reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021.
EU = Europe; ERoW = Established Rest of World; C5 = C5 inhibitors *Ultomiris* and *Soliris*; NMOSD = neuromyelitis optica spectrum disorder; gMG = generalised myasthenia gravis; PNH = paroxysmal nocturnal hemoglobinuria; aHUS = atypical hemolytic uremic syndrome; CER = constant exchange rates.
Collaboration partners: Merck & Co., Inc. (*Koselugo*).

Rare Disease – R&D highlights

Advancing expansion of *Ultomiris* in nephrology



Ultomiris

Phase II SANCTUARY trial in IgAN

Mean spot UPCR
24-hr (g/g)

over
26 WEEKS



rapid, complete and sustained complement inhibition at **week 4**

with key endpoints met:

- >40% **reduction** in **proteinuria**
- **stable eGFR**

Potential disease-modifying reduction in proteinuria

Data supports initiation of potential Phase III trial

IgAN | Abnormal IgA protein accumulates in kidneys, activating complement cascade



Complement system plays a clear role in the pathogenesis of IgAN

IgAN (diagnosed):

US	EU5	CN
>100k	>100k	>300k

significant unmet need for patients optimised on RAASi

mAb = monoclonal antibody; IgAN = immunoglobulin A neuropathy; UPCR = urine protein creatinine ratio; SE = standard error; eGFR = estimated glomerular filtration rate; IgA = immunoglobulin A; EU5 = France, Germany, Italy, Spain, United Kingdom; CN = China; RAASi = renin-angiotensin-aldosterone system inhibitors.

CEO
Closing Remarks



Pascal Soriot
CHIEF EXECUTIVE OFFICER

AstraZeneca

Focused investment in pipeline of the future, rich near-term Phase III catalyst flow

Near-term rich catalyst flow through 2024

LAURA	*EGFR*m NSCLC (unresectable Stg. III)	H1 2024
DESTINY-Breast06	HER2-low breast cancer (2L)	H1 2024
anselamimab (CAEL-101)	AL amyloidosis	H2 2024
TROPION-Breast02	TNBC (locally rec. inop./met.)	H2 2024
WAYPOINT	CRSwNP	H2 2024

Confident in delivering on our ambition for industry-leading growth

*EGFR*m = epidermal growth factor receptor mutation; NSCLC = non-small cell lung cancer; Stg. = Stage; HER2 = human epidermal growth factor receptor 2; 2L = 2nd-line; AL = light chain; TNBC = triple negative breast cancer; rec. = recurrent; innop. = inoperable; met. = mestastatic; CRSwNP = chronic rhinosinusitis with nasal polyps.

Question & Answer Session

Pascal Soriot
EXECUTIVE DIRECTOR & CHIEF EXECUTIVE OFFICER

Aradhana Sarin
EXECUTIVE DIRECTOR & CHIEF FINANCIAL OFFICER

Marc Dunoyer
CHIEF EXECUTIVE OFFICER, ALEXION

Susan Galbraith
EXECUTIVE VICE PRESIDENT, ONCOLOGY R&D

Dave Fredrickson
EXECUTIVE VICE PRESIDENT, ONCOLOGY BUSINESS

Sharon Barr
EXECUTIVE VICE PRESIDENT, BIOPHARMACEUTICALS R&D

Ruud Dobber
EXECUTIVE VICE PRESIDENT, BIOPHARMACEUTICALS BUSINESS

Iskra Reic
EXECUTIVE VICE PRESIDENT, VACCINES AND IMMUNE THERAPIES

Leon Wang
EXECUTIVE VICE PRESIDENT, INTERNATIONAL

Appendix

- Pipeline Highlights
- Oncology tumour maps
- Emerging Markets performance
- Key medicines performance by therapy area



Delivering on science-led innovation

Selected key pipeline highlights since Q2 2023 Results

Oncology BioPharmaceuticals Rare Disease



3 Breakthrough Designations (US):

Tagrisso
_EGFR_m NSCLC (1st-line) (FLAURA2)

Enhertu
HER2-overexpressing advanced or metastatic colorectal cancer (DESTINY-CRC02)

Enhertu
HER2-expressing tumours (DESTINY-PanTumour02)

6 regulatory approvals in major markets, including:

Lynparza (JP)
prostate cancer (1st-line) (PROpel)

Enhertu (EU, JP)
_HER2_m NSCLC (2nd-line+) (DESTINY-Lung02)

Calquence (CN)
CLL (ASCEND)

Forxiga (CN)
HFpEF (DELIVER)

Soliris (CN)
neuromyelitis optica spectrum disorder

_EGFR_m = epidermal growth factor receptor-mutated; HER2 = human epidermal growth factor receptor 2; _HER2_m = human epidermal growth factor receptor 2-mutated; NSCLC = non-small cell lung cancer; CLL = chronic lymphocytic leukaemia; HFpEF = heart failure with preserved ejection fraction. Collaboration partners: Daiichi Sankyo (_Enhertu_), Merck & Co., Inc. (_Lynparza_).

AstraZeneca in Lung Cancer

Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030

	resectable Stg. I-III	unresectable Stg. I-II	unresectable Stg. III	metastatic 1L	metastatic 2L+
Est. epi (G7)	~200K	~30K	~70K	~350K	~290K
IO sensitive c.70%	*Imfinzi* **AEGEAN** volrustomig + CTx **NEOCOAST-2**	*Imfinzi* w/ SBRT **PACIFIC-4**	CRT → *Imfinzi* **PACIFIC** CRT + *Imfinzi* **PACIFIC-2** *Imfinzi* combos **PACIFIC-8, -9** improvements across PD-L1 spectrum	*Imfinzi* + *Imjudo* + CTx **POSEIDON** Dato-DXd + IO **TROPION-Lung08/TROPION-Lung07/AVANZAR** *Enhertu* + IO + CTx **DESTINY-Lung03** volrustomig + CTx **eVOLVE-Lung02** rilvegostomig (PD1/TIGIT) **ARTEMIDE-1**	*Imfinzi* + ceralasertib **LATIFY** Dato-DXd **TROPION-Lung01** AZD9592 (EGFR/cMET ADC) **EGRET** sabestomig (PD1/TIM3)
*EGFR*m c.16%	*Tagrisso* **ADAURA** *Tagrisso* **neoADAURA**		CRT → *Tagrisso* **LAURA**	*Tagrisso* **FLAURA** *Tagrisso* + CTx **FLAURA2**	savolitinib + *Tagrisso* **SAFFRON/SAVANNAH** AZD9592 (EGFR/cMET ADC) **EGRET**
Other tumour drivers c.12%			CRT → *Imfinzi* **PACIFIC**		Dato-DXd **TROPION-Lung01** **TROPION-Lung05**
*HER2*m c.2%				*Enhertu* **DESTINY-Lung04**	*Enhertu* **DESTINY-Lung02**

established SoC

Leading the future of lung cancer treatment

- Establishing *Tagrisso* as backbone TKI in *EGFR*m
- *Imfinzi* leading IO in unresectable
- Advancing best-in-class ADCs to replace systemic chemotherapy
- Delivering next-wave bispecifics to improve on PD1/PD-L1
- Developing novel combinations, including IO + ADCs
- Investing behind new technologies and platforms, including cell therapy and testing/screening

Est epi (G7) = estimated epidemiology across G7 (US, EU5, JP); Stg. = stage; CTx = chemotherapy; SBRT = stereotactic body radiation therapy; CRT = chemoradiotherapy; pembro = pembrolizumab; IO = immunotherapy; ADC = antibody-drug conjugate; PD1 = programmed cell death protein 1; EGFR = epidermal growth factor receptor; c-MET = mesenchymal-epithelial transition factor; TIGIT = T-cell immunoreceptor with immunoglobulin and ITIM domains; CTLA4 = cytotoxic T-lymphocyte associated protein 4; TIM3 = T-cell immunoglobulin and mucin domain-containing protein 3; SoC = standard of care; TKI = tyrosine kinase inhibitor; *HER2*m = human epidermal growth factor receptor 2 mutated. Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Compugen (rilvegostomig).

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death

established SoC

	Early: Neoadjuvant	Early: Adjuvant	RECRURENCE	Metastatic: 1st line	Metastatic: 2nd line	Metastatic: 3rd line	Metastatic: 4th line +
Est. epi (G7)	540k			125k	90k	65k	55k
HER2-positive 15-20%	*Enhertu* ± THP **DESTINY-Breast11**	NST→ residual disease → *Enhertu* **DESTINY-Breast05**		*Enhertu* ± pertuzumab **DESTINY-Breast09**	*Enhertu* **DESTINY-Breast03**	*Enhertu* **DESTINY-Breast02**	
HR-positive 65-75% --- *HER2-low 1+, 2+* *60%*		Low risk: Good outcomes with current SoC CTx → camizestrant (± CDK4/6i) **CAMBRIA-2** CTx → AI (± CDK4/6i) 2-5 yrs → camizestrant **CAMBRIA-1**		camizestrant + CDK4/6i **SERENA-4** *ESR1m*: AI + CDK4/6i → camizestrant + CDK4/6i **SERENA-6** capivasertib + *Faslodex* + CDK4/6i **CAPItello292**	capivasertib + *Faslodex* **CAPItello291** *Enhertu* **DESTINY-Breast06** HER2-low IHC **0-1+**, 1+, 2+	Dato-DXd **TROPION-Breast01** *Enhertu* **DESTINY-Breast04** HER2-low IHC 1+, 2+	
TNBC 10-15% --- *HER2-low 1+, 2+* *35%*	Dato-DXd + *Imfinzi* **TROPION-Breast04**	NST → residual disease → Dato-DXd ± *Imfinzi* **TROPION-Breast03**		capivasertib + paclitaxel **CAPItello290** PD-L1+ 40%: Dato-DXd + *Imfinzi* **TROPION-Breast05** PD-L1- 60%: Dato-DXd **TROPION-Breast02**	HER2-Low		
gBRCAm *5% of HR-positive* *15% of TNBC*		CTx → *Lynparza* **OlympiA**		*Lynparza* **OlympiAD**			

All numbers are approximate. Illustrative settings and populations, not to scale.
1/2/3/4L = 1st/2nd/3rd/ 4th-line; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients. HER2 = human epidermal growth factor receptor 2; THP = docetaxel, trastuzumab, and pertuzumab; NST = neoadjuvant systemic treatment; HR = hormone receptor; SoC = standard of care; CTx = chemotherapy; AI = aromatase inhibitor; CDK4/6i = cyclin-dependent kinase 4 and 6 inhibitor; yrs = years; ESR1m = estrogen receptor 1 gene mutation; Dato-DXd = datopotamab deruxtecan; TNBC = triple negative breast cancer; PD-L1 = programmed cell death ligand 1; gBRCAm = germline BRCA-mutated.
Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Merck & Co., Inc. (*Lynparza*).

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death

	Early: Neoadjuvant	Early: Adjuvant		1st line	2nd line	3rd line	4th line +
Est. epi (G7)	405k			80k	65k	55k	50k

RECRURENCE

Less benefit from ET HR+ mBC

Low risk HR-positive

- Adjuvant: Current SoC drives good outcomes for patients with low risk HR-positive eBC. ***Low unmet need*** *and limited opportunity to add benefit*
- 1st line: ***Camizestrant to replace ET*** — camizestrant + CDK4/6i, **SERENA-4**
- 1st line: *ESR1m* — AI + CDK4/6i → camizestrant + CDK4/6i, **SERENA-6**

Intermediate / high risk HR-positive

- Neoadjuvant: ***Potential for ADCs to replace chemo***
- Adjuvant: ***Camizestrant to replace ET*** — CTx → camizestrant (+/- CDK4/6i), **CAMBRIA-2**
- Adjuvant: CTx → AI (+/- CDK4/6i) 2-5 yrs → camizestrant, **CAMBRIA-1**
- 1st line: ***Improve upon CDK4/6i + ET*** — capivasertib + *Faslodex* + CDK4/6i, **CAPItello292**

Metastatic:

- 2nd line: ***Address ET + CDK4/6i resistance*** — capivasertib + *Faslodex*, **CAPItello291**
- 2nd line: ***Replace chemotherapy*** — *Enhertu*, **DESTINY-Breast06**, HER2-low **0-1+**, 1+, 2+
- 3rd line / 4th line +: ***Replace chemotherapy*** — Dato-DXd, **TROPION-Breast01**
- 3rd line / 4th line +: ***Replace chemotherapy*** — *Enhertu*, **DESTINY-Breast04**, HER2-low 1+, 2+

Loss of clinical benefit to current ET

Loss of clinical benefit to current ET

All numbers are approximate. Illustrative settings and populations, not to scale.
HR = hormone receptor; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients; SoC = standard of care; ADC = antibody drug conjugate; ET = endocrine therapy; CTx = chemotherapy; AI = aromatase inhibitor; CDK4/6i = cyclin-dependent kinase 4 and 6 inhibitor; yrs = years; ESR1m = estrogen receptor 1 gene mutation; ER = estrogen receptor; Dato-DXd = datopotamab deruxtecan.
Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd).

Emerging Markets – 9M 2023

Total Revenue +10% at CER to $9.2bn, +20% at CER ex-COVID-19 medicines



Growth at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets.

Oncology

Tagrisso

10% growth at CER to $4,380m in 9M 2023



	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3
EM	315	325	406	400	406	356	444	408	409
ERoW	232	245	207	231	203	206	202	218	198
Europe	259	258	252	256	268	245	257	284	281
US	441	486	439	513	521	535	521	581	577

Imfinzi and Imjudo

56% growth at CER to $3,102m in 9M 2023



	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3
EM	78	65	58	75	90	63	81	102	87
ERoW	101	101	101	104	99	97	134	222	221
Europe	120	138	125	142	135	142	163	176	208
US	319	330	315	374	413	450	522	576	610

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.

Oncology

Lynparza

3% decrease at CER to $2,070m in 9M 2023



	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
EM	96	103	121	120	117	130	137	142	131
ERoW	67	71	66	72	64	66	68	77	71
Europe	155	161	160	169	164	162	178	187	178
US	270	294	270	312	314	331	268	311	322

Lynparza

Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential



	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
Sales Milestone	400	-	-	-	-	-	-	-
Regulatory Milestone	-	175	-	75	105	-	-	-

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.
Collaboration partners: Merck & Co., Inc. (*Lynparza*).

Oncology

Calquence

26% growth at CER to $1,839m in 9M 2023



	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
	2021		2022				2023		
EM	5	8	7	8	12	17	18	24	28
ERoW	4	8	13	18	18	20	22	27	30
Europe	37	43	55	67	79	86	108	117	128
US	308	336	339	396	457	465	384	485	468

Enhertu

>2x growth at CER to $919m in 9M 2023



	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
	2021		2022				2023		
EM	4	5	9	17	25	29	38	69	72
ERoW	-	-	1	2	2	3	3	5	9
Europe	9	13	20	26	31	33	55	70	79
US	45	49	57	73	124	151	161	178	179

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.
Collaboration partners: Daiichi Sankyo (*Enhertu*).

BioPharmaceuticals: Cardiovascular, Renal & Metabolism

Farxiga

41% growth at CER to $4,389m in 9M 2023



	2021		2022				2023		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
EM	320	318	391	423	410	441	498	578	579
ERoW	63	78	99	98	84	72	138	136	105
Europe	213	225	318	309	329	342	393	456	506
US	202	228	193	275	279	323	296	339	366

Brilinta

Stable at CER at $996m in 9M 2023



	2021		2022				2023		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
EM	76	71	69	78	76	64	82	79	64
ERoW	16	16	14	14	10	8	6	6	6
Europe	85	83	76	73	65	67	67	68	68
US	198	178	166	185	187	206	179	178	193

Lokelma

49% growth at CER to $300m in 9M 2023



	2021		2022				2023		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
EM	1	-	3	2	9	6	11	13	13
ERoW	13	15	15	18	17	18	20	24	22
Europe	3	5	6	7	8	9	11	14	16
US	32	34	39	39	45	48	56	49	51

 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.

BioPharmaceuticals: Respiratory & Immunology

Fasenra

13% growth at CER to $1,134m in 9M 2023



	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
EM	7	5	7	10	12	13	14	14	19
ERoW	41	43	37	36	35	35	35	36	35
Europe	75	75	75	78	77	76	88	89	86
US	199	234	189	230	229	257	201	267	249

Breztri

73% growth at CER to $478m in 9M 2023



	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
EM	14	15	22	21	28	21	38	43	42
ERoW	6	8	7	10	9	9	10	15	12
Europe	2	3	5	9	8	11	15	21	19
US	25	47	53	53	58	75	81	84	98

Tezspire

>5x growth at CER to $230m in 9M 2023



	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
EM	-	-	-	-	-	-	-	-	-
ERoW	-	-	-	-	-	2	4	8	10
Europe	-	-	-	-	-	2	7	11	11
US	-	-	3	13	26	37	43	62	74

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.
Collaboration partners: Amgen (*Tezspire*).

BioPharmaceuticals: Respiratory & Immunology

Symbicort

1% decrease at CER to $1,842m in 9M 2023



	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
EM	151	152	167	139	169	133	229	177	195
ERoW	96	96	91	98	91	95	79	86	81
Europe	155	171	157	155	133	137	147	137	123
US	274	262	259	222	237	255	233	200	156

Pulmicort

10% growth at CER to $493m in 9M 2023



	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023
EM	173	193	164	72	103	123	182	90	119
ERoW	12	13	13	12	12	12	9	11	11
Europe	15	23	18	17	14	19	20	16	13
US	17	19	22	15	16	12	10	7	5

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.

Rare Disease

Soliris

15% decrease at CER to $2,429m in 9M 2023



	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3
EM	53	117	71	63	84	83	115	99	124
ERoW	86	111	107	174	104	91	88	86	74
Europe	199	240	221	216	190	179	183	184	163
US	460	608	591	574	523	491	448	445	420

Ultomiris

58% growth at CER to $2,141m in 9M 2023



	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3
EM	5	4	24	6	4	4	13	17	17
ERoW	56	73	70	72	77	90	98	110	131
Europe	69	100	105	120	122	134	159	152	184
US	167	214	220	236	315	365	381	434	445

Strensiq

24% growth at CER to $847m in 9M 2023



	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3
EM	4	6	9	9	8	10	15	9	5
ERoW	15	20	19	19	19	19	21	22	21
Europe	16	20	19	21	18	19	21	21	22
US	124	173	161	193	192	224	205	248	237

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Q3 2021 Total Revenue shows the numbers reported by AstraZeneca following the acquisition of Alexion, which completed on 21 July 2021.
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.